Research partners advance two malaria vaccine candidates
The University of Oxford and ReciBioPharm, Recipharm’s Advanced Biologics division, are expanding their long-standing collaboration with the development of two blood-stage malaria vaccine candidates for Phase I/II clinical trials. Since 2016, the collaboration has delivered five vaccine candidates and will now actively progress the manufacture of R78C… Read More